Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease. Background: TROPIC evaluated the efficacy and safety of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback